海西新药宣布，其研发的Hx9428药物已获得美国食品药品监督管理局（FDA）批准，可开展针对新生血管性年龄相关性黄斑变性（nAMD）的临床试验申请（IND）。这一进展标志着该公司在眼科疾病治疗领域取得重要突破，为后续临床开发奠定基础。
海西新药宣布，其研发的Hx9428药物已获得美国食品药品监督管理局（FDA）批准，可开展针对新生血管性年龄相关性黄斑变性（nAMD）的临床试验申请（IND）。这一进展标志着该公司在眼科疾病治疗领域取得重要突破，为后续临床开发奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.